Burrill & Company (BCF IV GP), LLC

Burrill Capital Fund IV, L.P.

Shareholders in Portfolio Company 
RUSNANO, other investors

Industry Sector 
Special Funds

Production Location 
USA
Russian Federation

Investment Started:  2011

Total Budget

6.2  bln rubles
Co-investment by RUSNANO
2.5  bln rubles

Facilitating transfer of technology to Russia through equity capital investmens and contract manufacturing

This venture fund in medicine and biotechnology will invest primarily in companies in mid-stage development, facilitating transfer of Western nanotechnology to Russia and placement of contract production and services in the country through the establishment of joint businesses.

Companies developing innovative drugs, diagnostic medical equipment, and medical and industrial biotechnology will be the priorities for the fund’s investment. The products and technologies of portfolio companies will be targeted toward resolving vitally important issues for Russia’s population, particularly socially significant illnesses.

Areas in which fund invests

  • Medicine: treatment of cancers, cardiovascular diseases, ophthalmological diseases, diabetes, psychological and autoimmune conditions, trauma, HIV infection, hepatitis, and bacterial infections
  • Biotechnology

Competitive advantages

  • Burrill & Company’s extensive experience and $1.5 million portfolio of medical and biotechnical venture investments
  • Burrill & Company’s earnings record
  • Access, through Burrill, to potential co-investors and partners for RUSNANO

Fund’s lifetime: 10 years